This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023) |
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C82H110ClFN14O15 |
Molar mass | 1586.31 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Enlicitide chloride (INN; previously known as MK-0616) is a macrocyclic peptide investigational drug who is being evaluated for the treatment of hypercholesterolaemia. It is a PCSK9 inhibitor.
Merck has launched a Phase 3 clinical trial to evaluate the efficacy and safety of MK-0616 in Adults With Hypercholesterolemia.
References
- "Recommended International Nonproprietary Names: List 90" (PDF). WHO Drug Information. 37 (3): 753–754. ISBN 978-92-4-008139-0.
- Burnett JR, Hooper AJ (2023). "MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment". Expert Opinion on Investigational Drugs. 32 (10): 873–878. doi:10.1080/13543784.2023.2267972. PMID 37815341. S2CID 263802012.
- "A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids". ClinicalTrials.gov. 2024-05-17.
- "The MK-0616 Information Center". MK-0616.com. 2024-07-07.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |